SCHEMBL1967331

SCHEMBL1967331

COC(=O)c1c(O)c2cc(Cl)c(Cl)n2n(Cc2ccc(F)cc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.41
HSP90B1 P14625 2/20 0.41
MAPT P10636 4/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
P2RX3 P56373 1/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964633 0.84 MAPT (0.40) HSP90AA1HSP90B1MAPTTP53L3MBTL1
SCHEMBL3723620 0.83 KMT2A (0.43) HSP90AA1HSP90B1MAPTTP53L3MBTL1
SCHEMBL1967854 0.82 EGLN3 (0.52)
SCHEMBL1969294 0.80 HSP90AA1 (0.41) HSP90AA1HSP90B1MAPTTP53L3MBTL1
SCHEMBL3725348 0.79 KDM4E (0.40) HSP90AA1HSP90B1MAPTTP53L3MBTL1
SCHEMBL1965300 0.73 P2RX7 (0.42) HSP90AA1HSP90B1MAPTTP53L3MBTL1
SCHEMBL1964132 0.72 KMT2A (0.45) MAPTTP53L3MBTL1GAASMN1; SMN2
SCHEMBL3722498 0.70 AR (0.41) HSP90AA1HSP90B1MAPTGAASMN1; SMN2
SCHEMBL1965536 0.69 KDM4E (0.45) SMN1; SMN2KDM4EMEN1KMT2AP2RX3
SCHEMBL1963992 0.69 KDM4E (0.45) MAPTTP53SMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 HSP90AA1 147/4885HSP90B1 108/4885MAPT 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.